tiprankstipranks
Trending News
More News >
Hepion Pharmaceuticals (HEPA)
OTHER OTC:HEPA
Advertisement

Hepion Pharmaceuticals (HEPA) Price & Analysis

Compare
787 Followers

HEPA Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.18%<0.01%8.58%91.41%
0.18%
Insiders
8.58% Other Institutional Investors
91.41% Public Companies and Individual Investors

HEPA FAQ

What was Hepion Pharmaceuticals’s price range in the past 12 months?
Hepion Pharmaceuticals lowest stock price was $0.04 and its highest was $44.50 in the past 12 months.
    What is Hepion Pharmaceuticals’s market cap?
    Hepion Pharmaceuticals’s market cap is $658.58K.
      When is Hepion Pharmaceuticals’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Hepion Pharmaceuticals’s earnings last quarter?
      Currently, no data Available
      Is Hepion Pharmaceuticals overvalued?
      According to Wall Street analysts Hepion Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Hepion Pharmaceuticals pay dividends?
        Hepion Pharmaceuticals does not currently pay dividends.
        What is Hepion Pharmaceuticals’s EPS estimate?
        Hepion Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Hepion Pharmaceuticals have?
        Hepion Pharmaceuticals has 10,976,276 shares outstanding.
          What happened to Hepion Pharmaceuticals’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Hepion Pharmaceuticals?
          Currently, no hedge funds are holding shares in HEPA

          Company Description

          Hepion Pharmaceuticals

          Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
          Similar Stocks
          Company
          Price & Change
          Follow
          Biodexa Pharmaceuticals
          NovaBay Pharma
          Kazia Therapeutics
          Titan Pharmaceuticals
          NLS Pharmaceutics
          Popular Stocks
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis